Project Grant W81XWH1710054

This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...

This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...

This $429,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to investigate the role of Schwann cell PIEZO1 in pain sensation. The key objectives are to: 1) develop and validate adeno-associated virus (AAV) vectors for selective inhibition of Schwann cell PIEZO1, and 2) determine the sensory effects of Schwann cell...

This $1,559,917 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to develop a topical neurokinin-1 receptor (NK1R) antagonist as a non-addictive analgesic treatment for chronic ocular pain. The key objectives are to assess the analgesic efficacy of the NK1R antagonist and determine its effects on the ocular surface-trigeminal ganglion neurosensory pathway. The project is...

The National Cancer Institute (NCI) awarded a $179,403 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to the University of Nebraska Medical Center (UNMC) to develop and screen novel flupirtine analogue compounds as non-opioid analgesics for treating chemotherapy-induced neuropathic pain (CINP). The 2-year project aims to synthesize and evaluate flupirtine analogues that can effectively relieve CINP while mitigating the liver toxicity concerns associated with the parent...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $387,000.00 to Florida Atlantic University to develop novel intranasal delivery cyclic peptide analgesics for pain management. The research aims to create new peptide-based pain medications that combine kappa-opioid receptor agonist activity with serotonin and/or norepinephrine delivery, with the goal of improving pain relief while minimizing...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $444,125 in funding to Duke University to explore the role of the LRRC55 regulatory protein in pain pathways. The key objectives are to: 1) delineate LRRC55's function in chronic pain behaviors using genetically-modified mice, 2) quantify changes in LRRC55 expression in dorsal root ganglion and spinal cord neurons...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $3,565,780 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a groundbreaking high-frequency trans-spinal magnetic stimulation (HF-TSMS) system for the non-invasive treatment of neuropathic pain. The funded project aims to create an HF-TSMS tool that can target neural pathways involved in...

Federal Grant Award Summary Navega Therapeutics, Inc. received a $297,327 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), awarded on September 18, 2025, with completion scheduled for August 31, 2026. The company will reformulate NT-Z001, an epigenetic gene therapy, to enable localized intra-articular joint injections rather than the more invasive intrathecal...

The National Institute on Drug Abuse (NIDA) awarded a $7.99 million Cooperative Agreement to The Washington University (awarded September 1, 2025, with completion by August 31, 2027) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop negative allosteric modulators (NAMs) at the mu opioid receptor as a therapeutic approach to treat opioid overdose and opioid use disorder (OUD). The research builds on the identification of a first-in-class NAM compound designated...